Minerva Neurosciences, Inc (NASDAQ:NERV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

According to Zacks, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company’s pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson’s disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. “

A number of other equities research analysts have also issued reports on the stock. BidaskClub lowered shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. JMP Securities restated an “outperform” rating and issued a $20.00 target price (up previously from $17.00) on shares of Minerva Neurosciences in a research note on Thursday, June 1st. Finally, ValuEngine lowered shares of Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research note on Monday, May 29th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. Minerva Neurosciences currently has a consensus rating of “Hold” and an average target price of $14.58.

Minerva Neurosciences (NASDAQ NERV) opened at 6.05 on Friday. The firm’s 50-day moving average price is $6.84 and its 200 day moving average price is $7.97. The stock’s market capitalization is $257.18 million. Minerva Neurosciences has a 12-month low of $5.55 and a 12-month high of $14.92.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.07. During the same quarter last year, the business posted ($0.18) earnings per share. On average, equities analysts anticipate that Minerva Neurosciences will post ($1.19) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Minerva Neurosciences, Inc (NERV) Downgraded by Zacks Investment Research to “Hold”” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/01/minerva-neurosciences-inc-nerv-downgraded-by-zacks-investment-research-to-hold.html.

Several large investors have recently made changes to their positions in the stock. Federated Investors Inc. PA increased its stake in shares of Minerva Neurosciences by 18.2% in the second quarter. Federated Investors Inc. PA now owns 7,535,287 shares of the biopharmaceutical company’s stock worth $66,687,000 after buying an additional 1,162,364 shares in the last quarter. FMR LLC increased its stake in shares of Minerva Neurosciences by 13.7% in the second quarter. FMR LLC now owns 5,660,794 shares of the biopharmaceutical company’s stock worth $50,098,000 after buying an additional 680,000 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Minerva Neurosciences by 39.0% in the second quarter. Franklin Resources Inc. now owns 1,158,100 shares of the biopharmaceutical company’s stock worth $10,249,000 after buying an additional 325,000 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Minerva Neurosciences by 14.4% in the second quarter. Vanguard Group Inc. now owns 1,074,239 shares of the biopharmaceutical company’s stock worth $9,507,000 after buying an additional 134,942 shares in the last quarter. Finally, Nexthera Capital LP increased its stake in shares of Minerva Neurosciences by 53.6% in the first quarter. Nexthera Capital LP now owns 757,200 shares of the biopharmaceutical company’s stock worth $6,133,000 after buying an additional 264,242 shares in the last quarter. 69.29% of the stock is owned by institutional investors and hedge funds.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Receive News & Stock Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related stocks with our FREE daily email newsletter.